Medicenna Therapeutics (MDNAF) vs. The Competition Financial Analysis

Medicenna Therapeutics (OTCMKTS:MDNAF) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare Medicenna Therapeutics to related businesses based on the strength of its earnings, profitability, valuation, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

35.9% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 33.1% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Medicenna Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Medicenna Therapeutics	N/A	-$8.48 million	-6.00
Medicenna Therapeutics Competitors	$432.12 million	-$67.78 million	-10.60

Medicenna Therapeutics’ rivals have higher revenue, but lower earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Medicenna Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	1	0	0	2.00
Medicenna Therapeutics Competitors	4896	9966	15989	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.92%. Given Medicenna Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Medicenna Therapeutics has less favorable growth aspects than its rivals.

Volatility & Risk

Medicenna Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics’ rivals have a beta of 5.42, indicating that their average stock price is 442% more volatile than the S&P 500.

Profitability

This table compares Medicenna Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	-142.13%	-90.31%
Medicenna Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Summary

Medicenna Therapeutics rivals beat Medicenna Therapeutics on 8 of the 13 factors compared.

About Medicenna Therapeutics

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.